Table 1.

Baseline characteristics of the clinical trial populations

BENEDICT, n=742DIRECT (T1D), n=3093DIRECT (T2D), n=1758ALTITUDE, n=3654IRMA-2 Trial, n=565
Men, n (%)397 (53.5)1771 (57.3)858 (48.1)2497 (68.3)391 (69.2)
Age, yr, n (%)61.9 (8.0)31.0 (8.4)56.9 (7.7)65.8 (9.4)58.1 (8.6)
Diastolic BP, mmHg, n (%)88.8 (7.7)73.1 (6.9)78.0 (7.0)74.1 (10.0)89.6 (9.3)
Systolic BP, mmHg, n (%)152.4 (14.0)116.9 (9.6)132.7 (13.5)138.2 (16.3)152.7 (14.6)
Albuminuriaa5.2 [3.5–8.8]b4.5 [3.5–7.0]b5 [3.5–8.0]b23.7 [4.11–73.6]c58.0 [33.0–102.0]c
Normoalbuminuria, n (%)742 (100)3093 (100)1758 (100)1020 (27.9)0 (0)
Microalbuminuria, n (%)0 (0)0 (0)0 (0)2634 (72.1)565 (100)
Hemoglobin A1c, n (%)3.0 (1.4)8.3 (1.6)8.2 (1.6)7.9 (1.7)7.0 (1.7)
Total cholesterol, mg/dl, n (%)211.8 (36.5)184.8 (37.5)204.9 (42.5)170.5 (46.4)223.2 (44.4)
eGFR, ml/min per 1.73 m2, n (%)81.4 (15.3)80.8 (13.7)70.0 (14.2)55.4 (20.6)70.5 (12.4)
  • T1D, type 1 diabetes; T2D, type 2 diabetes.

  • a Presented as median and interquartile range.

  • b Urinary albumin excretion rate: micrograms per minute.

  • c UACR: milligrams per gram.